IL-6/STAT3 Signaling Contributes to Sorafenib Resistance in Hepatocellular Carcinoma Through Targeting Cancer Stem Cells
Yu Li,1 Gang Chen,1 Zhijian Han,2 Huijuan Cheng,2 Liang Qiao,3 Yumin Li1,2 1General Surgery Department, Lanzhou University Second Hospital, Lanzhou, Gansu, People’s Republic of China; 2Key Laboratory of Digestive System Tumors of Gansu Province, Lanzhou University Second Hospital, Lanzhou,...
Main Authors: | Li Y, Chen G, Han Z, Cheng H, Qiao L |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2020-09-01
|
Series: | OncoTargets and Therapy |
Subjects: | |
Online Access: | https://www.dovepress.com/il-6stat3-signaling-contributes-to-sorafenib-resistance-in-hepatocellu-peer-reviewed-article-OTT |
Similar Items
-
IL-6/STAT3 Signaling Contributes to Sorafenib Resistance in Hepatocellular Carcinoma Through Targeting Cancer Stem Cells [Corrigendum]
by: Li Y, et al.
Published: (2020-11-01) -
LncRNA DANCR Promotes Sorafenib Resistance via Activation of IL-6/STAT3 Signaling in Hepatocellular Carcinoma Cells
by: Liu Y, et al.
Published: (2020-02-01) -
Phloretin attenuates STAT-3 activity and overcomes sorafenib resistance targeting SHP-1–mediated inhibition of STAT3 and Akt/VEGFR2 pathway in hepatocellular carcinoma
by: Sarita Saraswati, et al.
Published: (2019-10-01) -
Sorafenib for Egyptian patients with advanced hepatocellular carcinoma; single center experience
by: Omar Abdel-Rahman, et al.
Published: (2014-03-01) -
Sorafenib in the treatment of advanced hepatocellular carcinoma
by: Mousa Ali
Published: (2008-01-01)